Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Launched by ADAPTIMMUNE · Jan 2, 2018
Trial Information
Current as of June 18, 2025
Terminated
Keywords
ClinConnect Summary
This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who have received lentivirus-mediated genetically engineered T Cell Receptors in an Adaptimmune sponsored clinical trial. The study is designed in accordance with FDA and EMA guidance on gene therapy trials.
The study involves up to 15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated gene transfer in Adaptimmune clinical studies. The study will include subjects who have received various T cell receptors including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T. Su...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects must have received T cell receptor therapy in an Adaptimmune clinical study
- • Subjects who have provided informed consent prior to their study participation
- Exclusion Criteria:
- • Not applicable
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company specializing in the development of innovative T-cell therapies for cancer treatment. Leveraging its proprietary SPEAR T-cell platform, Adaptimmune aims to harness the power of the immune system to target and eliminate cancer cells with precision. The company is focused on advancing its pipeline of engineered T-cell therapies through rigorous clinical trials, demonstrating a commitment to improving patient outcomes in oncology. With a strong emphasis on scientific excellence and collaboration, Adaptimmune is dedicated to transforming the landscape of cancer immunotherapy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nashville, Tennessee, United States
Houston, Texas, United States
Toronto, Ontario, Canada
Patients applied
Trial Officials
Marcus Butler, MD
Principal Investigator
Princess Margaret Cancer Centr
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials